tbuckley/cabot-search huggingface dataset:
Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer.
Authors: A. K. Morgans, M. L. Hancock, G. Barnette, M. S. Steiner, R. A. Morton, M. R. Smith
Journal: Journal of Clinical Oncology (2011)

212 Background: In the general population, black men have higher bone mineral density (BMD) and lower fracture rates than white men. Whether race influences bone loss and fracture risk during androgen deprivation therapy (ADT) for prostate cancer is unknown. Using data from a recently completed prospective, randomized, clinical trial we compared BMD and fracture rates of black and white men receiving ADT for prostate cancer. Methods: Subjects in these analyses (n=516) were members of the placebo group of a two-year randomized controlled trial of toremifene to prevent fractures in men receiving ADT for prostate cancer. All subjects resided in United States and reported their race as either black (n=68) or white (n=448). We compared baseline characteristics, including BMD and prevalent vertebral fractures, between black (n=68) and white men (n=448). We also compared changes in BMD and rates of new vertebral fractures over the two year study period. Results: Black men had higher baseline hip BMD than white men (0.98 ± 0.15 g/m 2 and 0.91 ± 0.15 g/m 2 , respectively; p=0.001). Black men had similar BMD of the spine (1.09 ± 0.22 g/m 2 and 1.11 ± 0.22 g/m 2 in black and white men, respectively; p=0.51), but fewer prevalent vertebral fractures (7.4% versus 15.0%; p=0.13). Changes in BMD from baseline to 24 months were similar between black and white men (total hip percentage change −2.54 ± 0.26 in white men and −2.09 ± 0.60 in black men; p=0.55; lumbar spine percentage change −1.30 ± 0.33 in white men and −1.67 ± 0.71 in black men; p&lt;0.71). Rates of new vertebral fractures trended towards being lower in black men (1.15% of black men versus 4.83% of white men; relative risk 0.24; p&lt;0.12). Conclusions: Among men receiving ADT for prostate cancer, black men had higher baseline BMD at the hip and fewer prevalent vertebral fractures. Changes in BMD during ongoing ADT were similar for black and white men. Consistent with lower baseline risk for fracture, however, black men had fewer new vertebral fractures than white men. [Table: see text]
Importance of Determining Maximal Heart Rate for Providing a Standardized Training Stimulus—Reply
Authors: Hui-Jie Zhang, Xue-Jun Li, Xiao-Ying Li
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Use Of 46/1 Haplotype Permits To Follow JAK2V617F Clonal Architecture In PV Patients: Clonal Evolution and Impact Of IFNα Treatment
Authors: Salma Hasan, Bruno Cassinat, Jean-Pierre Le Couédic, Fabrizia Favale, Barbara Monte-Mor, Catherine Lacout, Eric Solary, Jean-Luc Villeval, Nicole Casadevall, Jean-Jacques Kiladjian, William Vainchenker, Isabelle Plo
Journal: Blood (2013)
Extramammary Paget's disease of the penis and anogenital area: SEER analysis.
Authors: V. A. Master, L. Herrel, T. V. Johnson, K. A. Delman
Journal: Journal of Clinical Oncology (2011)

220 Background: Extramammary Paget's disease (EMPD) is a rare cancer with poorly described outcomes comprising primarily single-institution small case series. We used the Surveillance, Epidemiology, and End Results (SEER) registries to further define survival and predictors of survival in EMPD. Methods: 17 SEER registries were queried for male patients diagnosed with EMPD from 1973 to 2007. Patients were categorized by: penis and anogenital structures (anorectum, scrotum, and skin). Descriptive analyses were conducted to characterize each group including age, year of diagnosis, race, tumor stage, and treatment. Kaplan-Meier and multivariate Cox regression analyses were performed. Results: The cohort consisted of 328 patients. Overall survival based on primary sites of EMPD were: anorectum (24.3%), scrotum (62.4%), penis (62.5%), skin (50.8%). Controlling for patient and disease characteristics, significant factors negatively impacting survival were primary site in the anorectal region compared to scrotum, penis and skin (p&lt;0.001, p=0.008, p=0.005 respectively), presence of distant disease versus localized disease (p=0.01) and radiation only (RT) treatment versus surgery alone (p=0.016). Survival benefit was not increased in patients who underwent combined RT and surgery treatment, as compared to those who were treated with surgery alone (p=0.61). Conclusions: Predictors of lower survival in men with EMPD in this cohort include anorectal location, distant disease and RT-only treatment. RT in addition to surgery does not appear to confer increased survival. [Table: see text] No significant financial relationships to disclose.
Clinicopathological Features of Nodular Sclerosis-Type Classical Hodgkin Lymphoma In the Elderly: Multicenter Study of Hodgkin Lymphoma In Japan
Authors: Naoko Asano, Tomohiro Kinoshita, Koichi Ohshima, Tadashi Yoshino, Nozomi Niitsu, Norifumi Tsukamoto, Kaoru Hirabayashi, Koji Izutsu, Yasuo Morishima, Tadashi Matsushita, Shigeo Nakamura
Journal: Blood (2010)
Scl/Tal1 Directly Activates Hematopoiesis and Represses Cardiogenesis During Mesodermal Diversification
Authors: Tonis Org, Dan Duan, Amelie Montel-Hagen, Roberto Ferrari, Ben Van Handel, Rajkumar Sasidharan, Stuart H. Orkin, Siavash Kurdistani, Hanna Mikkola
Journal: Blood (2012)
3-Phosphoinositide-Dependent Protein Kinase 1 (PDPK1) Is a Pivotal Cell Signaling Mediator in Multiple Myeloma
Authors: Yoshiaki Chinen, Junya Kuroda, Yuji Shimura, Hisao Nagoshi, Miki Kiyota, Mio Yamamoto-Sugitani, Shinsuke Mizutani, Natsumi Sakamoto, Masaki Ri, Eri Kawata, Tsutomu Kobayashi, Yosuke Matsumoto, Shigeo Horiike, Shinsuke Iida, Masafumi Taniwaki
Journal: Blood (2014)
Do urologists and radiation oncologists agree on adjuvant radiation therapy for prostate cancer? A web-based patterns-of-care survey.
Authors: T. N. Showalter, K. A. Teti, K. A. Foley, S. W. Keith, E. J. Trabulsi, A. Dicker, C. D. Lallas, L. Pizzi, L. G. Gomella
Journal: Journal of Clinical Oncology (2011)

76 Background: Three randomized trials support adjuvant radiation therapy (ART) over observation after radical prostatectomy (RP) for prostate cancer (PC) patients with adverse pathologic features (APFs), but many clinicians instead favor early salvage RT (SRT) for a rising PSA. We conducted a web-based survey of U.S. radiation oncologists (RO) and urologists (U) regarding ART and SRT. Methods: We designed a web-based survey to evaluate beliefs about post-RP RT and treatment policies. Survey invitations were e-mailed to SUO members and a list of 926 RO ASTRO members with an interest in PC. One email was sent to limit message burden. Only those responses at least 50% complete were included in the analysis. Differences in ART recommendation rates were evaluated by chi square test. Results: Responses were received from 231 RO and 101 U, resulting in 302 analyzable responses (88 U, 214 RO). 79% of U and 32% of RO respondents were academic physicians. ART was recommended based on APF alone (78% RO, 44% U), based on APF plus Gleason score or PSA (14% RO, 35% U), only for detectable PSA (7% RO, 14% U), or never (2% RO, 7% U). When asked the effect of ART on outcomes, most respondents replied “improves survival” (71% RO, 63% U) or “improves biochemical control but not survival” (29% RO, 30% U), but 9% of U replied “delays PSA recurrence, but no durable benefit” or “no improvement in any outcomes” (versus 0% RO). A recommendation for ART based on APFs alone was made for: seminal vesicle invasion (SVI) (76% RO, 59% U; p=0.003), extracapsular extension (ECE) (70% RO, 32% U; p&lt;0.001), positive surgical margin (PSM) (91% RO, 48% U; p&lt;0.002). For patients with Gleason score 8-10 PC, ART was recommended for: SVI (75% RO, 56% U; p=0.001), ECE (73% RO, 45% U; p&lt;0.001), PSM (93% RO, 74% U; p&lt;0.001). Reported PSA threshold for SRT was: any detectable (36% RO, 23% U), 0.2-0.3 (50% RO, 36% U), 0.4-0.5 (9% RO, 30% U), 0.6-0.8 (3% RO, 10% U) ng/mL, or higher (1% RO, 1% U). Conclusions: Despite similar rates of belief that ART improves survival or biochemical control, U were less likely than RO to recommend ART based solely on APFs after RP. Upcoming results of clinical trials of ART versus SRT may provide consensus for decisions in this setting. No significant financial relationships to disclose.
5-FU induced encephalopathy during 5-FU containing regimen for esophageal squamous cell carcinoma.
Authors: Ken Kato, Kohei Akiyoshi, Nobukazu Hokamura, Hiroyasu Igaki, Yuji Tachimori, Yoshitaka Honma, Satoru Iwasa, Tetsuya Hamaguchi, Yasuhide Yamada, Yasuhiro Shimada
Journal: Journal of Clinical Oncology (2012)

138 Background: 5-FU induced encephalopathy was known as uncommon toxicity during the treatment which contain with 5-FU. But there were few reports such as clinical feature and risk factors of 5-FU induced encephalopathy. We conducted retrospective case-control study to investigate the clinical feature and risk factor of them. Methods: Data was collected by medical record. The selection criteria were as follows: Pathologically proven esophageal squamous cell carcinoma, patents who received 5-FU containing regimen in our hospital. The diagnostic criteria of the 5-FU induced encephalopathy includes: (i) development of encephalopathy during or shortly after completion of 5-FU administration; (ii) exclusion of other metabolic factors that may affect consciousness and (iii) exclusion of an adverse effect by concomitant medications. 5-FU containing regimens include that 5-FU+CDDP with or without radiation, 5-FU=Nedaplatin with or without radiation and 5-FU=CDDP=docetaxel. Results: From January 2008 to March 2010, 317 patients were collected. Of 317 patients, the median age was 64 (range 36-79); male/female: 267/49; cStage I/IIA/IIB/III/IV: 63/19/53/91/85. Median and total course of 5-FU containing regimen and were 2 (range1-14) and 943. The object of first treatment was as follows; Neoadjuvant (n=114), definitive chemoradiotherapy (n=110), palliative chemotherapy (n=81) and others (N=24). Nine patients (2.8%) were diagnosed as 5-FU encephalopathy. The median course and time to onset of encephalopathy was 3 course (range1-4) and 5 days (range 3-6) from start of 5-FU. Five of 6 pts who examined NH 3 were observed the elevation of NH 3 . All patients recovered within 1-2 days after stopping administration of 5-FU. Head CT or MRI showed no abnormality in all pts. Univariate analysis showed that only age (&gt;60) was risk factor for encephalopathy. The other thing such as regimen and sex were not associated with encephalopathy. Conclusions: This is the first report which described 5-FU induced encephalopathy in such large population. 5-FU encephalopathy was very rare but recovered with adequate treatment. In aged patients we should pay more attention about 5-FU encephalopathy than younger patients.
Pfizer is fined £84m for “exploiting opportunity” to hike price of phenytoin
Authors: Nigel Hawkes
Journal: BMJ (2016)

The drug giant Pfizer has been fined £84.2m (€99m; $106.8m) by the Competition and Markets Authority (CMA) for charging excessive prices for a drug used by 48 000 UK patients with epilepsy. Flynn Pharma, Pfizer’s partner in a plan to boost prices of phenytoin sodium by 2600%, has been fined £5.2m.

Pfizer said that it would appeal the ruling and the record fine, arguing that the drug was making a loss and that the deal provided a way of ensuring a continuing supply. When Flynn launched the drug as a generic—placing it outside the rules that apply to branded drugs—the price charged was 25-40% less than that of another supplier, Pfizer said …
Pleomorphic lobular breast carcinoma: A review of 35 cases at a single institution.
Authors: J. A. Cox, M. A. Eltorky, M. J. Wolski, J. D. Sturgeon, M. M. Joyner, A. B. Markowitz, S. S. Hatch
Journal: Journal of Clinical Oncology (2011)

175 Background: Pleomorphic lobular carcinoma (PL) is an aggressive subtype of invasive lobular carcinoma. A previous report of 52 patients showed an increase in development of metastases for pleomorphic lobular carcinoma patients. There are relatively few case series reporting on this aggressive form of breast cancer. This report features a descriptive and survivorship comparison of a large case series of PL reviewed by a single breast pathologist. Methods: From 1993-2010 we retrospectively reviewed 198 cases of invasive lobular carcinomas, 35 cases (34 patients with one patient presenting with 2 independent cancers) of PL and 163 cases of non-pleomorphic invasive lobular carcinoma (NPL). The pathology was reviewed by a single breast pathologist and classified as either PL or NPL according to WHO classification. Kaplan-Meier survivals were computed and compared with a log rank test using SPSS 18. Overall survival (OS) was computed from date of diagnosis to date of last update (02/01/11). Progression free survival (PFS) until either local or metastatic failure was also computed. Results: The median follow-up was 59.5 months and 73 months, for NPL and PL patients respectively. The median age of diagnosis was 55 (range 40-80) and 58.67 (range 36-89) for PL and NPL groups. Of the NPL group, 75.5% were post-menopausal as opposed to 67.6% in the PL group. PL cases were ER positive 87.1% vs. 90.1% of the NPL cases. Her-2/neu status was known in nearly 50% of cases with 17 positive NPL cases and 5 positive PL cases. Clinical stage at presentation was stage IIB or less in 67.6% of the PL patients and 80.1% of the NPL patients. Six patients presented (17.6%) with metastatic disease in the PL group and 12 patients (7.7%) in the NPL group. None of the descriptive comparisons above were significantly different by χ 2 analysis. PFS at 5 years was 30% and 21% in PL and NPL patients, respectively (p=0.73). OS at 5 years was 68.5% for PL patients and 83.9% for NPL patients (p=0.031). Conclusions: In this large case series of PL cases reviewed by a single breast pathologist, PL patients showed a statistically significant decreased OS, but no significant difference in PFS, at 5 years from diagnosis.
Significant Activity of Lenalidomide-Dexamethasone in Multiple Myeloma (MM) Patients with Light Chain Induced Acute Renal Failure (LC-ARF)
Authors: Heinz Ludwig, Elisabeth Rauch, Thomas Kuhr, Adalbert Weissman, Daniel Heintel, Niklas Zojer, Hedwig Kasparu, Richard Greil, Zdenek Adam
Journal: Blood (2012)
A phase I study to evaluate safety and antitumor activity of biweekly BMS-936558 (Anti-PD-1, MDX-1106/ONO-4538) in patients with RCC and other advanced refractory malignancies.
Authors: D. F. McDermott, C. G. Drake, M. Sznol, J. A. Sosman, D. C. Smith, J. D. Powderly, D. M. Feltquate, G. Kollia, A. K. Gupta, J. Wigginton
Journal: Journal of Clinical Oncology (2011)

331 Background: Programmed death-1 (PD-1), a T-cell inhibitory receptor, may suppress antitumor immunity. BMS-936558, a fully human PD-1 blocking antibody, has shown antitumor activity and manageable toxicity after biweekly dosing (Sznol, ASCO 2010, #2506). This report provides an update on safety and antitumor activity with special emphasis on RCC. Methods: An open-label phase I dose escalation study of BMS-936558 was conducted in patients (pts) with treatment refractory metastatic clear-cell renal cell carcinoma (RCC), castrate-resistant prostate cancer (CRPC), melanoma (MEL), non-small cell lung cancer, or colorectal cancer (CRC). Dose escalation continued to 10 mg/kg when an expansion cohort for pts (16) with each tumor type was opened for additional safety and efficacy information. Tumor response (RECIST) was evaluated every 8 weeks. Clinically stable pts with early PD could continue until further PD or clinical deterioration. Results: 126 pts (18 RCC) were treated with 1, 3, or 10 mg/kg. MTD was not reached. Across all doses, the most common AEs (Any/grade 3-4) were fatigue (45.2%/6.3%) and diarrhea (30.2%/0.8%) while the most common drug-related AEs (Any/grade 3-4) were fatigue (20.6%/0.8%), rash (11.9%/0%), pruritus (11.3%/0%), and diarrhea (10.3%/0.8%). There was no apparent relationship between dose and frequency of AEs. One pt died with sepsis while being treated for drug-related grade 4 pneumonitis. The median number of prior treatment regimens in the RCC cohort was 2 (range 1-6). Of the 18 RCC pts, 16 were treated with 10 mg/kg. The median duration of treatment was 7.6+mo. ORR was 5/16 (31.2%) and SD&gt;4mo was 6/16 (37.5%). The median duration of response was 4.0+ mo (3.7-7.4+ mo). Of the 2 RCC pts treated with 1 mg/kg, 1 obtained a CR (12+ mo) and 1 had SD (21+ mo). For evaluable CRPC pts, 1/15 pts (6.7%) obtained a PR (2+ mo) and 3/15 (20%) had SD&gt;4mo. Conclusions: BMS-936558 administered biweekly is tolerable and has encouraging antitumor activity in a previously treated patients with RCC. Data on baseline characteristics, long-term toxicity and response duration will be updated at the meeting. [Table: see text]
The effects of body mass index on pretreatment characteristics, treatment choice, and response to treatment of intermediate- and high-grade prostate cancer.
Authors: Katherine Cox Ansley, Emma Holliday Ramahi, Gregory P. Swanson, Joseph W. Basler, Fei Du
Journal: Journal of Clinical Oncology (2012)

142 Background: The relationship between obesity and prostate cancer outcomes remains unclear. A retrospective cohort study was performed to determine the effect of body mass index (BMI) on patients with intermediate to high-grade prostate cancer. Methods: Our retrospective study cohort included 1077 men from the South Texas Veteran’s Healthcare System Tumor Registry diagnosed with Gleason 7-10 prostate cancer in 1998-2008 and treated with either radical prostatectomy (RP), radiation therapy (RT) or hormone therapy (HT). Mean follow up was 4.6 ± 2.7 years. Patients were stratified into four groups on the basis of their BMI at the time of prostate cancer diagnosis (&lt;25, 25-30, 30-35 or &gt;35). Statistical analysis included Kruskal-wallis test and Pearson’s Chi-square test. Results: There was an inverse relationship between PSA and BMI at diagnosis; however, we found no difference in Gleason score at diagnosis. There was a difference in the primary treatment modality chosen between the BMI groups. Primary treatment modality decision was likely influenced by PSA at diagnosis, among other pre-treatment characteristics. Patients with a BMI &gt;35 were significantly less likely to undergo RP. However, after controlling for age, primary treatment modality, Gleason score, pre-treatment PSA and diabetes diagnosis, there was no difference in overall mortality. Conclusions: Patients with an increasing BMI have a lower PSA at diagnosis, are less likely to receive RP but do not have significantly worse overall survival.
High Serum Levels of Extracellular Vesicles which Express Specific Markers of Malignancy Are Released in Patients with Various Types of Hematological Neoplastic Disorders
Authors: Antonella Caivano, Luciana De Luca, Ilaria Laurenzana, Francesco La Rocca, Vittorio Simeon, Stefania Trino, Annalisa Morano, Fiorella D'Auria, Pellegrino Musto, Luigi Del Vecchio
Journal: Blood (2014)
Are we seeing more obese breast cancer patients in Brooklyn?
Authors: R. Sultana, M. Thwin, G. M. Villani, M. A. Grand, N. M. Tun
Journal: Journal of Clinical Oncology (2011)

182 Background: Breast cancer is the most common female cancer in the US and the second most common cause of cancer death in women. Obesity has become a significant health challenge. The prevalence of obesity among non-Hispanic black women is reported to be approximately 50% with a prevalence of Class lll obesity of 5.2%. The objective of this study was to evaluate the severity of obesity in female breast cancer patients at our facility over the last three years. Methods: A retrospective study was conducted on 191 patients treated between January 2008 and December 2010 for breast cancer. Prevalence of obesity by class (Class I = BMI from 30 to 34.99 kg/m 2 , Class II = BMI from 35 to 39.99 kg/m 2 , Class IIl= BMI greater than 39.99 kg/m 2 ) was calculated. Pearson chi-square statistic was used to investigate the relation between classes of obesity and stages of breast cancer (early stage = CIS to stage 2, advanced stage = stage 3 and 4). Results: Data from 191 breast cancer patients with BMI of 30 or more were analyzed. Class I constituted 39.3%, Class II 34% and class III 26.7%. The majority (75.9%) were diagnosed at an early stage, 24.1% diagnosed with advanced stage. Severity of obesity was not associated with the stage of breast cancer at diagnosis (c 2 = 0.004, df = 2, n = 191, p &gt; 0.5). African American women constituted the majority (78.5%) of our study population. Conclusions: Our study reveals an alarming rate of class lll obesity among our breast cancer patients. It does not show a correlation among obesity and stage of disease, The majority of patients have early stage, potentially curable breast cancer. Given the fact that obesity has been associated with an increase in mortality (cardiovascular mortality is 50% greater in obese people and 90% greater in severely obese persons in comparison with that for people of average weight) our study suggests that treatment of obesity may play an equally important role in achieving long term outcomes as treatment of breast cancer itself.